Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System

Documenti analoghi

• Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
  di: Fadini, Gian Paolo, et al.
  Pubblicazione: (2019)
• Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions
  di: Fadini, Gian Paolo, et al.
  Pubblicazione: (2018)
• Upper and/or lower gastrointestinal adverse events with glucagon‐like peptide‐1 receptor agonists: Incidence and consequences
  di: Horowitz, Michael, et al.
  Pubblicazione: (2017)
• SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
  di: Bonora, Benedetta Maria, et al.
  Pubblicazione: (2021)
• Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice
  di: Morieri, Mario Luca, et al.
  Pubblicazione: (2020)